Global Adoption of Biologicals Accelerates as Marrone Bio’s Grandevo® WDG Bioinsecticide is Approved for Use in New Zealand, Chile and on Hemp in…

DAVIS, Calif., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Marrone Bio Innovations (NASDAQ: MBII) (MBI), a global provider of bio-based crop protection and plant health products, today announced that it recently received approval for Grandevo WDG Bioinsecticide for use in New Zealand and Chile. Grandevo WDG and Grandevo CG have also been approved for use on hemp by the U.S. Environmental Protection Agency (EPA).

The rest is here:
Global Adoption of Biologicals Accelerates as Marrone Bio’s Grandevo® WDG Bioinsecticide is Approved for Use in New Zealand, Chile and on Hemp in...

Ceapro Inc. to Present at NobleCon17

Live video webcast with President and CEO, Gilles Gagnon on Wednesday, January 20th at 11:15 AM ET Live video webcast with President and CEO, Gilles Gagnon on Wednesday, January 20th at 11:15 AM ET

See the rest here:
Ceapro Inc. to Present at NobleCon17

Theratechnologies to Present at the B. Riley Securities Virtual Oncology Investor Conference

MONTREAL, Jan. 14, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Paul Levesque, President and Chief Executive Officer and Dr. Christian Marsolais, Senior Vice President and Chief Medical Officer will present at the B. Riley Virtual Oncology Investor Conference on Wednesday, January 20, 2021 at 3:30 p.m. ET.

Link:
Theratechnologies to Present at the B. Riley Securities Virtual Oncology Investor Conference

RoosterBio Partners with Sartorius to Advance Cell and Gene Therapy Manufacturing

RoosterBio’s innovative hMSCs and bioprocess media systems, coupled with Sartorius’s scalable closed system bioreactor, downstream processing, and analytics, offers end-to-end hMSC manufacturing solutions for the field of regenerative medicine. RoosterBio’s innovative hMSCs and bioprocess media systems, coupled with Sartorius’s scalable closed system bioreactor, downstream processing, and analytics, offers end-to-end hMSC manufacturing solutions for the field of regenerative medicine.

Read this article:
RoosterBio Partners with Sartorius to Advance Cell and Gene Therapy Manufacturing

Dr. Han Myint Appointed as NextCure’s Chief Medical Officer

BELTSVILLE, Md., Jan. 14, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the appointment of Dr. Han Myint, MD, FACP as chief medical officer. Dr. Myint will oversee the clinical development of key products in NextCure’s product pipeline, including NC318, a first-in-class immunomedicine, targeting Siglec-15 (S15), and NC410, recombinant LAIR-2 fusion protein designed to block immune suppression mediated by the immune modulator LAIR-1. Prior to joining NextCure, Dr. Myint held senior roles at both Celgene (a Bristol Myers Squibb Company) and NexImmune Inc.

Read the original post:
Dr. Han Myint Appointed as NextCure’s Chief Medical Officer

Tauriga Sciences Inc. Completes Payment for the Entirety of its Initial Production Run of its Caffeine Infused Version of Tauri-Gum

Link:
Tauriga Sciences Inc. Completes Payment for the Entirety of its Initial Production Run of its Caffeine Infused Version of Tauri-Gum

DBV Technologies Provides Update on Investigational Viaskin™ Peanut for Children Ages 4-11 Years

Montrouge, France, January 14, 2021

Follow this link:
DBV Technologies Provides Update on Investigational Viaskin™ Peanut for Children Ages 4-11 Years

Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Jan. 14, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced the grant of inducement stock options exercisable for an aggregate of 18,500 shares of Albireo’s common stock. The stock options are exercisable at a price of $37.22 per share, the closing price of Albireo’s common stock on January 11, 2021, the grant date, and were granted as inducements material to the employee’s acceptance of employment with Albireo in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has a 10-year term and vests over a four-year period, subject to the employee’s continued service with Albireo through the applicable vesting dates. The vesting schedule for each stock option is 25 percent on the one-year anniversary of the employee’s start date with Albireo and 75 percent in 12 equal quarterly installments thereafter. The stock options are subject to the terms and conditions of Albireo’s 2020 Inducement Equity Incentive Plan.

Original post:
Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

ERYTECH Announces First Patient Enrolled in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer

ERYTECH Announces First Patient Enrolled in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer

See the original post:
ERYTECH Announces First Patient Enrolled in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer

Qilian International Holding Group Limited Announces Closing of Initial Public Offering

Jiuquan, China, Jan. 14, 2021 (GLOBE NEWSWIRE) -- Qilian International Holding Group Limited (the “Company”) (Nasdaq: QLI), a China-based pharmaceutical and chemical products manufacturer, today announced the closing of its initial public offering ("Offering") of 5,000,000 ordinary shares at a public offering price of US$5.00 per share.

Read more here:
Qilian International Holding Group Limited Announces Closing of Initial Public Offering